Elderly vs Non-Elderly Ulcerative Colitis Patient Outcomes on Tacrolimus, 2009-2017

Clinical data from a multicenter retrospective cohort study comparing the safety and efficacy of oral tacrolimus induction therapy in elderly (≥60 years, n=34) and non-elderly (<60 years, n=182) patients with moderate-to-severe ulcerative colitis. The dataset includes comparisons of clinical remission rates at week 12, colectomy-free survival at week 52, and adverse event incidence. The supplementary material was uploaded by figshare admin karger and is licensed under CC-BY-4.0.

Use Cases

• Compare clinical remission rates between age groups based on the reported 58.8% vs 56.6% outcomes at week 12.
• Analyze colectomy-free survival differences based on the reported 91.2% vs 90.7% rates at week 52.
• Investigate associations between baseline characteristics (e.g., comorbidity burden, hemoglobin, albumin levels) and treatment outcomes in elderly patients.
• Assess the safety profile of tacrolimus by comparing the incidence of adverse events leading to treatment discontinuation between groups.

Strengths

• Includes data from a multicenter study with 216 total patients (34 elderly, 182 non-elderly).
• Reports specific, comparable outcome metrics: clinical remission at week 12 and colectomy-free survival at week 52.
• Compares key baseline characteristics like comorbidity burden, hemoglobin, and albumin levels between groups.

Limitations

• Row count and column-level documentation are unknown; field semantics must be inferred after download.
• Data covers a specific time range (2009-2017) and its current relevance for clinical practice may require verification.
• The dataset is very small (63.6 KB), indicating limited scope and likely summary-level data rather than individual patient records.

Provenance

Source

figshare admin karger

Collection Method

Multicenter retrospective cohort study subanalysis.

Time Range

2009 to 2017

Freshness

Last updated 2026-04-28 07:55:29; freshness should be verified.